Australia's Neuren soars as partner Acadia wins FDA nod for Rett syndrome treatment

Neuren Pharmaceuticals

15/12/2025 24:42

** Shares of Neuren Pharmaceuticals NEU.AX soar as much as 3.8% to A$19.73, post their biggest intraday pct gain since Dec 5
** Co says partner Acadia Pharmaceuticals ACAD.O received U.S. FDA approval for DAYBUE STIX (trofinetide) for oral solution
** DAYBUE STIX is a powder formulation for treatment of Rett syndrome, a rare genetic disorder that affects brain development
** Co receives royalties on net sales
** YTD, shares up 57.6%

 (Reporting by Nichiket Sunil in Bengaluru)

 ((Nichiket.Sunil@thomsonreuters.com))